Filana Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Filana Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Filana Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Filana Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Filana Therapeutics Inc (Filana Therapeutics), formerly Cassava Sciences Inc, is a clinical-stage biotechnology company focused on detecting and treating central nervous system disorders. The company develops therapeutic and diagnostic products for conditions such as blood-based diagnostics to detect Alzheimer’s Disease and Tuberous Sclerosis Complex-related epilepsy. Filana Therapeutics' major products include the therapeutic drug candidate simufilam and the investigational diagnostic product candidate SavaDx. The company's products are primarily aimed at healthcare providers and researchers working in the field of neurodegenerative diseases. The company operates in various geographic locations, with patent protections in the US, Europe, Australia, Israel, Canada, and Japan. Filana Therapeutics is headquartered in Austin, Texas, the US.
Headquarters
United States of America
Address
Building 1, 6801 North Capital of Texas Highway, Austin, 78731
Website
www.filanatx.com
Telephone
1 512 5012444
No of Employees
17
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FLNA (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-273.7%
(2024 vs 2023)
Market Cap*
$49.3M
Net Profit Margin (0 vs)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Filana Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Simufilam: tuberous sclerosis complex (TSC)-related epilepsy |
| SavaDx: Blood-based Diagnostic to Detect Alzheimer’s Disease |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company signed a licensing agreement with Yale University, which provides intellectual property rights, including the rights to an issued US patent for a treatment method that may use simufilam for addressing seizures associated with rare neurodevelopmental disorders. |
| 2024 | Others | In March, the company completed an interim safety review of simufilam in ongoing Phase 3 clinical trials in patients with Alzheimer’s disease. |
| 2023 | Others | In May, the company finished dosing patients in its cognition maintenance study (CMS) of simufilam for the treatment of Alzheimer’s disease and dementia. |
Competitor Comparison
| Key Parameters | Filana Therapeutics Inc | Eli Lilly and Co | Pfizer Inc | Novartis AG | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United States of America |
| City | Austin | Indianapolis | New York City | Basel | Thousand Oaks |
| State/Province | Texas | Indiana | New York | Basel-Stadt | California |
| No. of Employees | 17 | 50,605 | 75,000 | 75,267 | 31,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Claude Nicaise, M.D. | Chairman | Executive Board | 2024 | 74 |
| Richard J. Barry | Chief Executive Officer; President; Director | Executive Board | 2021 | 67 |
| Eric J. Schoen | Chief Financial Officer | Senior Management | 2018 | 57 |
| R. Christopher Cook | Chief Legal Officer; Chief Operating Officer | Senior Management | 2022 | 62 |
| Joseph Hulihan | Chief Medical Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer